ALPN — Alpine Immune Sciences Share News
0.000.00%
Last trade - 00:00- $4.46bn
- $4.15bn
- $58.88m
Media: Alpine Immune is weighing options after takeover interest - Bloomberg News
Alpine Immune Sciences Inc reports results for the quarter ended in December - Earnings Summary
Alpine Immune Sciences Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Alpine Immune Sciences Announces Amendment Of Acazicolcept Option And License Agreement With Abbvie
Brief: Alpine Immune Sciences Q3 EPS USD -0.24
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Olaplex, Datadog
U.S. STOCKS ON THE MOVE-Uber, Olaplex, Planet Fitness
Alpine Immune drops on pricing $150 mln share offering
Brief: Alpine Immune Sciences Announces Pricing Of $150 Mln Public Offering
Brief: Alpine Immune Sciences Announces Proposed Public Offering
U.S. RESEARCH ROUNDUP- Booking Holdings, Eli Lilly, Markel Group
U.S. RESEARCH ROUNDUP-Beacon Roofing Supply, Bioxcel Therapeutics, Cambium Networks
Brief: Alpine Immune Sciences Q2 EPS USD -0.27
Alpine Immune Sciences Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Alpine Immune Sciences To Present Data From Ruby-1, A Phase 1 Study Of Povetacicept, At Upcoming Scientific Congresses
Alpine Immune Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Alpine Immune Sciences Reports First Quarter 2023 Financial Results
Brief: Alpine Immune Sciences posts Q1 EPS USD -0.28
Alpine Immune Sciences Inc expected to post a loss of 37 cents a share - Earnings Preview